These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22943280)

  • 1. Ceftazidime for respiratory infections.
    Choi SH; Koh Y
    Expert Opin Pharmacother; 2012 Oct; 13(14):2097-109. PubMed ID: 22943280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
    Guo W; He Q; Wang Z; Wei M; Yang Z; Du Y; Wu C; He J
    Am J Infect Control; 2015 Apr; 43(4):358-64. PubMed ID: 25838134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.
    Lin JC; Yeh KM; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2001 Jun; 34(2):131-7. PubMed ID: 11456359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Pfaller MA; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):63-8. PubMed ID: 16650951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
    Bassetti M; Righi E; Rosso R; Mannelli S; Di Biagio A; Fasce R; Pallavicini FB; Marchetti F; Viscoli C
    Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.
    Oostdijk EA; de Smet AM; Blok HE; Thieme Groen ES; van Asselt GJ; Benus RF; Bernards SA; Frénay IH; Jansz AR; de Jongh BM; Kaan JA; Leverstein-van Hall MA; Mascini EM; Pauw W; Sturm PD; Thijsen SF; Kluytmans JA; Bonten MJ
    Am J Respir Crit Care Med; 2010 Mar; 181(5):452-7. PubMed ID: 19965807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in acute lower respiratory tract infection.
    Colardyn F
    J Chemother; 1995 Jun; 7 Suppl 2():129-35. PubMed ID: 8622101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging issues in the management of infections caused by multi-drug-resistant, gram-negative bacilli.
    Rice LB
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-37-47. PubMed ID: 23577496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon.
    Piéboji JG; Koulla-Shiro S; Ngassam P; Adiogo D; Njine T; Ndumbe P
    Int J Infect Dis; 2004 May; 8(3):147-54. PubMed ID: 15109589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.